245
Participants
Start Date
January 31, 2008
Primary Completion Date
August 31, 2008
Study Completion Date
August 31, 2008
insulin glargine
Treat-to-target dose titration scheme, s.c. injection.
insulin degludec
Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
insulin degludec
Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
insulin degludec
Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
metformin
Tablets, 1500-2000 mg/day
Novo Nordisk Investigational Site, Johannesburg
Novo Nordisk Investigational Site, Durban
Novo Nordisk Investigational Site, Durban
Novo Nordisk Investigational Site, Newport News
Novo Nordisk Investigational Site, Greensboro
Novo Nordisk Investigational Site, Simpsonville
Novo Nordisk Investigational Site, Jacksonville
Novo Nordisk Investigational Site, Kingsport
Novo Nordisk Investigational Site, Milwaukee
Novo Nordisk Investigational Site, Chicago
Novo Nordisk Investigational Site, Chicago
Novo Nordisk Investigational Site, Springfield
Novo Nordisk Investigational Site, Dallas
Novo Nordisk Investigational Site, San Antonio
Novo Nordisk Investigational Site, Los Angeles
Novo Nordisk Investigational Site, Inglewood
Novo Nordisk Investigational Site, Spring Valley
Novo Nordisk Investigational Site, Redlands
Novo Nordisk Investigational Site, Medford
Novo Nordisk Investigational Site, Renton
Novo Nordisk Investigational Site, Mumbai
Novo Nordisk Investigational Site, Hyderabad
Novo Nordisk Investigational Site, Vellore
Novo Nordisk Investigational Site, Kochi
Novo Nordisk Investigational Site, Idaho Falls
Novo Nordisk Investigational Site, Cambridge
Novo Nordisk Investigational Site, Etobicoke
Novo Nordisk Investigational Site, Toronto
Novo Nordisk Investigational Site, Toronto
Lead Sponsor
Novo Nordisk A/S
INDUSTRY